TGTX TG Therapeutics Inc.

11.50
-0.25  -2%
Previous Close 11.75
Open 11.80
Price To book 10.18
Market Cap 791612770
Shares 68,835,893
Volume 756,474
Short Ratio 15.37
Av. Daily Volume 1,130,524

SEC filingsSee all SEC filings

  1. 8-K - Current report 171069391
  2. 8-K - Current report 171021839
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017891
  4. 8-K - Current report 171016461
  5. 8-K - Current report 17994965

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial open for enrollment - noted September 14, 2017.
TG-1101 - ULTIMATE II
Multiple Sclerosis
Phase 1/2 initiated October 2016.
TGR-1202
Relapsed or refractory lymphoma - cancer
Phase 3 trial open for enrollment - noted September 14, 2017.
TG-1101 - ULTIMATE I
Multiple Sclerosis
Phase 2b enrollment commenced June 2016. First interim analysis August 10, 2017 determined that enrollment in TGR-1202 arm will stop but continue in TG-1101 + TGR-1202 arm. TGR-1202 arm replaced by combo of TG-1101, TGR-1202, and bendamustine.
TG-1101 and TGR-1202 - UNITY-DLBCL study
Diffuse large B-cell lymphoma (DLBCL) cancer
Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017. Meeting with FDA in 2H 2017.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3 completion of target enrollment announced September 5, 2017. Enrollment to continue through to mid-October with top-line data due 2Q 2018.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)

Latest News

  1. TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment
  2. Should You Buy TG Therapeutics Inc (TGTX) Now?
  3. TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
  4. TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting
  5. ETFs with exposure to TG Therapeutics, Inc. : September 1, 2017
  6. TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  7. TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017
  8. Edited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT
  9. TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial
  10. TG Therapeutics reports 2Q loss
  11. TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
  12. Investor Network: TG Therapeutics, Inc. to Host Earnings Call
  13. What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
  14. TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update
  15. TG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : August 4, 2017
  16. TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017
  17. TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS)
  18. ETFs with exposure to TG Therapeutics, Inc. : July 25, 2017
  19. TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : July 21, 2017

SEC Filings

  1. 8-K - Current report 171069391
  2. 8-K - Current report 171021839
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017891
  4. 8-K - Current report 171016461
  5. 8-K - Current report 17994965
  6. 8-K - Current report 17922130
  7. 8-K - Current report 17914826
  8. EFFECT - Notice of Effectiveness 17910205
  9. CORRESP [Cover] - Correspondence
  10. S-3/A [Amend] - Registration statement under Securities Act of 1933 17903129